Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule

We have read with great interest the paper by Ihara et al. [ [1] Ihara K. Ohtani S. Watanabe N. Takahashi N. Miyazaki N. Takemura R. Hori S. Nakahara J. Takizawa T. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J. Neurol. Sci. 2023; 453120811https://doi.org/10.1016/j.jns.2023.120811 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar ] entitled “Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing”. The authors retrospectively reviewed the clinical data of 15 patients with migraine who initially responded well to monthly galcanezumab but later switched to quarterly fremanezumab (n = 13) to reduce the number of hospital visits for monthly galcanezumab dosing or to monthly fremanezumab (n = 2) to avoid side effects related to galcanezumab. The results showed that the significant MMD reduction from baseline to the initiation of galcanezumab (−6.9 days) was maintained after switching to fremanezumab over 4 months (−6.2 days), with minor side effects and favorable tolerability.